Investors & Media

Stock Info
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
Aug 1, 2022

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

May 31, 2022

Analyses accounting for ALSFRS-R floor effect in ALS yields new results to be presented at the ENCALS meeting in Edinburgh, Scotland Clinical, biomarker and preclinical data from NurOwn® Phase 2...

May 16, 2022

BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn® Strengthened executive team in...

View All

Monday, August 15, 2022
8:00am - 9:00am EDT

Participant Numbers:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 955552

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds